Already a member?
Sign in
Listeria Cancer Vaccine Receives Approval for Phase I/II Testing in Cervical Cancer
Source: Genetic Engineering News
Date: 02/23/06
Headline: Advaxis' Listeria Cancer Vaccine Receives
Regulatory Approval for Phase I/II Testing in Cervical Cancer
Advaxis, Inc. (OTCBB: ADXS) announced that regulators have allowed the company to initiate Phase I/II clinical testing with its lead compound, Listeria-based cancer vaccine, Lovaxin C. Lovaxin C, which specifically targets cervical cancer in women, will be tested for the first time in humans in this study.
Date: 02/23/06
Headline: Advaxis' Listeria Cancer Vaccine Receives
Regulatory Approval for Phase I/II Testing in Cervical Cancer
Advaxis, Inc. (OTCBB: ADXS) announced that regulators have allowed the company to initiate Phase I/II clinical testing with its lead compound, Listeria-based cancer vaccine, Lovaxin C. Lovaxin C, which specifically targets cervical cancer in women, will be tested for the first time in humans in this study.
Louise |
Latest page update: made by Louise
, Feb 23 2006, 3:59 PM EST
(about this update
About This Update
name too long
- Louise
No content added or deleted. - complete history) |
|
Keyword tags:
cancer vaccine
Cervical cancer
Clinical trial
Lovaxin C
More Info: links to this page
|
